| Customization: | Available |
|---|---|
| Dosage Form: | Injection |
| Dossier: | Ready |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Amikacin Sulfate Injection 500mg/2ml |
| Strength | 500mg/2ml |
| Packing | 1vial/box |
| Origin | China |
This product is suitable for severe infection caused by Pseudomonas aeruginosa and some other pseudomonas, Escherichia coli, Proteus, Klebsiella, Enterobacter, Serratia, acinetobacter and other sensitive gram-negative bacilli and Staphylococcus (methicillin-sensitive strains). Such as bacteremia or sepsis, bacterial endocarditis, lower respiratory tract infection, bone and joint infection, biliary tract infection, abdominal infection, complex urinary tract infection, skin and soft tissue infection, etc. Because it is stable to most aminoglycoside inactive enzymes, it is particularly suitable for the treatment of severe infections caused by Gram-negative bacilli against kanamycin, gentamicin or tobramycin resistant strains.
Usage and dosage:
1. For adults, intramuscular injection or intravenous drip. For simple urinary tract infection, 0.2g (1 count) every 12 hours for patients with common antimicrobial resistance; For other systemic infections 7.5mg/kg every 12 hours, or 15mg/kg every 24 hours. Adults should not exceed 1.5g (7.5 sticks) a day, and the treatment course should not exceed 10 days.
2. For children, intramuscular injection or intravenous drip. The first dose was 10mg/kg by body weight, followed by 7.5mg/kg every 12 hours, or 15mg/kg every 24 hours.
3. Patients with renal dysfunction: creatinine clearance [50 ~ 90ml/min] were given 60% ~ 90% of the normal dose (7.5mg/kg) every 12 hours; The creatinine clearance rate of 10 to 50ml/min was 20 to 30% of 7.5mg/kg every 24 to 48 hours.
1. Cross allergy, patients who are allergic to one aminoglycoside may also be allergic to other aminoglycosides.
2. The following checks should be paid attention to in the process of medication:
(1) Routine urine and renal function tests to prevent severe nephrotoxic reactions.
(2) Hearing examination or electroacoustic examination, especially paying attention to high-frequency hearing impairment, which is particularly important for elderly patients.
3. Blood concentration should be monitored during the course of treatment when conditions permit, especially in neonates, the elderly and patients with renal decline. The peak concentration (Cmax) and trough concentration of 7.5mg/kg should be kept at 15-30 μg/ml and 5-10 μg/ml every 12 hours. The peak blood concentration of 15mg/kg once a day should be maintained at 56-64 μg/ml, and the trough concentration should be [1μg/ml].
4. This product should be used with caution under the following conditions:
(1) Water loss can increase blood drug concentration, easy to produce toxic reactions.
(2) No. 8 cerebral nerve damage, because this product can cause vestibular nerve and auditory nerve damage.
(3) Myasthenia gravis or Parkinson's disease, which can cause neuromuscular blocking, resulting in skeletal muscle weakness.
(4) For patients with renal function impairment, this product has renal toxicity.
Medication for special population:
This product belongs to class D for pregnant women, that is, it has certain harm to human beings, but the advantages may outweigh the disadvantages. This product may cross the placenta to reach fetal tissue and may cause fetal hearing impairment. Pregnant women must fully weigh the pros and cons before using this product. Lactating women use drugs to suspend breastfeeding.
Drug interaction:
1. This product can increase ototoxicity, nephrotoxicity and neuromuscular block when used in combination with other aminoglycosides or when applied successively locally or throughout the body.
2. The combination of this product with neuromuscular blocking drugs can aggravate the neuromuscular blocking effect, resulting in muscle weakness, respiratory depression and other symptoms. When used in combination with capreomycin, cisplatin, ethanic acid, furosemide or vancomycin (or norvancomycin), or when used locally or systematically successively, it may increase ototoxicity and renal toxicity.
3. Topical or systemic use of this product with cephalothiophene or cefzolin may increase renal toxicity. This product should not be mixed with amphotericin B, cephalothiophene, sulfadiazine, tetracycline and other injections, not in the same bottle.
){kind=link}